4-122743912-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 5 ACMG points: 5P and 0B. PM2PP3_ModeratePP5
The ENST00000314218.8(BBS12):c.2020C>T(p.Arg674Cys) variant causes a missense change. The variant allele was found at a frequency of 0.0000124 in 1,606,442 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R674H) has been classified as Uncertain significance.
Frequency
Consequence
ENST00000314218.8 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 5 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
BBS12 | NM_152618.3 | c.2020C>T | p.Arg674Cys | missense_variant | 2/2 | ENST00000314218.8 | NP_689831.2 | |
BBS12 | NM_001178007.2 | c.2020C>T | p.Arg674Cys | missense_variant | 3/3 | NP_001171478.1 | ||
BBS12 | XM_011531680.3 | c.2020C>T | p.Arg674Cys | missense_variant | 2/2 | XP_011529982.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
BBS12 | ENST00000314218.8 | c.2020C>T | p.Arg674Cys | missense_variant | 2/2 | 1 | NM_152618.3 | ENSP00000319062 | P1 | |
BBS12 | ENST00000542236.5 | c.2020C>T | p.Arg674Cys | missense_variant | 3/3 | 2 | ENSP00000438273 | P1 |
Frequencies
GnomAD3 genomes AF: 0.0000197 AC: 3AN: 152186Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000122 AC: 3AN: 245746Hom.: 0 AF XY: 0.00000754 AC XY: 1AN XY: 132700
GnomAD4 exome AF: 0.0000117 AC: 17AN: 1454256Hom.: 0 Cov.: 32 AF XY: 0.0000166 AC XY: 12AN XY: 722722
GnomAD4 genome AF: 0.0000197 AC: 3AN: 152186Hom.: 0 Cov.: 33 AF XY: 0.0000135 AC XY: 1AN XY: 74342
ClinVar
Submissions by phenotype
not provided Pathogenic:1Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jun 18, 2015 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Dec 09, 2015 | The R674C variant in the BBS12 gene has been reported previously in the homozygous state in two siblings with Bardet-Biedl syndrome. These siblings also harbored another BBS12 variant in cis with R674C as well as a heterozygous variant in BBS1 (Billingsley et al., 2010). The R674C variant was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The R674C variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. In silico analysis predicts this variant is probably damaging to the protein structure/function. The R674C variant is a strong candidate for a pathogenic variant, however the possibility it may be a rare benign variant cannot be excluded. - |
Retinal dystrophy Pathogenic:1
Likely pathogenic, criteria provided, single submitter | clinical testing | Blueprint Genetics | Mar 26, 2019 | - - |
BBS12-related disorder Uncertain:1
Uncertain significance, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Apr 18, 2024 | The BBS12 c.2020C>T variant is predicted to result in the amino acid substitution p.Arg674Cys. This variant has been reported in the homozygous state in two siblings affected with Bardet-Biedl syndrome, who also carried an additional BBS12 homozygous missense change (p.Val400Met; Billingsley et al 2010. PubMed ID: 20472660). Although no definitive conclusions have been drawn, in silico predictions and reports from other laboratories suggest that the p.Arg674Cys variant may be more likely to be the causative variant, and p.Val400Met may be more likely benign. This variant is reported in 0.0062% of alleles in individuals of African descent in gnomAD. It has conflicting interpretations in ClinVar of Likely Pathogenic and Uncertain (https://www.ncbi.nlm.nih.gov/clinvar/variation/281596/evidence/). Although we suspect that this variant may be pathogenic, at this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Oct 27, 2021 | The c.2020C>T (p.R674C) alteration is located in exon 2 (coding exon 1) of the BBS12 gene. This alteration results from a C to T substitution at nucleotide position 2020, causing the arginine (R) at amino acid position 674 to be replaced by a cysteine (C). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Bardet-Biedl syndrome 12 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Counsyl | Oct 16, 2017 | - - |
Bardet-Biedl syndrome Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 08, 2019 | This sequence change replaces arginine with cysteine at codon 674 of the BBS12 protein (p.Arg674Cys). The arginine residue is highly conserved and there is a large physicochemical difference between arginine and cysteine. This variant is present in population databases (rs759088490, ExAC 0.01%). This variant has been observed to segregate with Bardet-Biedl syndrome in a family (PMID: 20472660). ClinVar contains an entry for this variant (Variation ID: 281596). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be disruptive, but these predictions have not been confirmed by published functional studies and their clinical significance is uncertain. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at